araag2/HINT huggingface dataset:
Clinical trial NCT00446680 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: mannitol, placebo
SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Written informed consent

          -  Confirmed diagnosis of cystic fibrosis

          -  Aged > 6 years

          -  FEV1 >30 % and < 90% predicted

          -  Able to perform all the techniques necessary to measure lung function

        Main Exclusion Criteria:

          -  "Terminally ill" or listed for lung transplantation

          -  Had a lung transplant

          -  Using nebulised hypertonic saline

          -  Significant episode of haemoptysis (>60 mL) in the three months prior to enrolment

          -  Recent myocardial infarction or cerebral vascular accident

          -  Breast feeding or pregnant, or plan to become pregnant while in the study
             participating in another investigative drug study, parallel to, or within 4 weeks of
             study entry

          -  Allergy or intolerance to mannitol

          -  Using beta blockers

          -  Have a condition or be in a situation which in the Investigator's opinion may put the
             subject at significant risk, may confound results or may interfere significantly with
             the patient's participation in the study
Clinical trial NCT00085891 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is able to provide written informed consent before beginning any study related
             procedures

          -  Patient has a documented clinical diagnosis of schizophrenia

          -  Patient is able to understand and comply with the requirements of the study, as judged
             by a study investigator

        Exclusion Criteria:

          -  Patients with a history of non-compliance as judged by the study investigator

          -  Patients with a known lack of response to previous treatment with quetiapine

          -  Patients who have participated in another drug study within 4 weeks prior to
             enrollment into this study

          -  Patients who have previously participated in this study or study D1444C00132
Clinical trial NCT00378690 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: leuprorelin acetate
SMILES: CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

        At study entry (visit 1):

          -  Written informed consent

          -  Male subjects aged >=18 and <80 years old

          -  Locally advanced (stage T3 or T4) prostate cancer or Relapsing prostate cancer
             following radical prostatectomy or,Relapsing prostate cancer following radiotherapy

          -  Gleason score of >=6

          -  ECOG performance status of 0-2.

          -  Life expectancy at least 5 years

        At randomization (visit 4):

          -  Two successive decreasing serum PSA levels <=1 ng/ml

        Exclusion Criteria:

        At study entry (visit 1):

          -  Any suspected second primary tumors

          -  Evidence of metastatic disease

          -  Other malignancy within the last 5 years except

          -  Acute spinal cord compression, uni- or bilateral ureteric obstruction

          -  Any concurrent biological response modifier therapy

          -  Concurrent chemotherapy

          -  Less than 1 year since any prior neoadjuvant or adjuvant hormonal therapy

          -  Less than 6 months since prior 5-alpha reductase inhibitor treatment

          -  Other concurrent hormonal therapy

          -  Any concurrent radiotherapy

          -  Testosterone at screening <= 1.7 mM or 50 ng/dL

          -  Clinically significant elevation of serum creatinine or liver enzymes

          -  Hypersensitivity to GnRH or other GnRH analogues or leuprorelin acetate

          -  Hypersensitivity to CASODEXâ 50 mg.
Clinical trial NCT00621504 (phase 3, status: completed)
Conditions: bacterial pneumonia
ICD codes: J15.9, P23.6
Drugs: ceftaroline fosamil for injection, iv ceftriaxone, placebo, clarithromycin
SMILES: [H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

        Subjects are required to meet the following inclusion criteria:

          -  Community-acquired pneumonia

          -  initial hospitalization, or treatment in an emergency room or urgent care setting

          -  infection would require initial treatment with IV antimicrobials.

        Exclusion Criteria:

        Subjects must NOT meet any of the following exclusion criteria:

          -  CAP suitable for outpatient therapy with an oral antimicrobial agent

          -  respiratory tract infections not due to community-acquired bacterial

          -  Non-infectious causes of pulmonary infiltrates

          -  Pleural empyema

          -  Infection with an atypical organism

          -  History of any hypersensitivity or allergic reaction to any ß-lactam antimicrobial

          -  History of any hypersensitivity or allergic reaction to clarithromycin or any
             macrolide/ ketolide
Clinical trial NCT00364351 (phase 3, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vandetanib, erlotinib
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed locally advanced or metastatic NSCLC

          -  Failure of at least one but not more than two prior chemotherapy regimens

        Exclusion Criteria:

          -  Prior treatment with erlotinib (Tarceva), gefitinib (IRESSA), sunitinib (Sutent),
             sorafenib (Nexavar)

          -  Chemotherapy or other type of anti cancer therapy within 4 weeks of study start
Clinical trial NCT00232596 (phase 3, status: completed)
Conditions: seizures
ICD codes: G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: retigabine, placebo
SMILES: CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or
             without secondary generalization

          -  28-day partial seizure frequency rate of four or more partial seizures over the 8-week
             baseline phase

          -  Currently treated with up to three established AEDs

          -  Vagal Nerve Stimulator may be included

        Exclusion Criteria:

          -  Existing medical or psychiatric condition which could affect patient's health or
             compromise ability to participate in the study

          -  Clinically significant abnormalities on physical exam, vital signs, ECG, or liver
             function tests

          -  Impaired renal function (creatinine clearance less than 50 mL/minute)

          -  Evidence of progressive central nervous disease, lesion, or encephalopathy

          -  History of primary generalized seizures

          -  History of clustering or flurries or status epilepticus within 12 months of study
             entry
Clinical trial NCT00463567 (phase 2/phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive, copd, lung diseases, obstructive
ICD codes: J44.9, J44.1, J44.0, G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol, formoterol (12 µg b.i.d.), tiotropium (18 µg o.d.), placebo to indacaterol, placebo to formoterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure

          -  Co-operative outpatients with a diagnosis of COPD (moderate to severe as classified by
             the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines,
             2005) and:

               -  Smoking history of at least 20 pack years

               -  Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value.

               -  Post-bronchodilator FEV1/FVC < 70% (Post refers to within 30 min of inhalation of
                  400 µg of salbutamol)

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to
             Visit 1 or during the run-in period

          -  Patients requiring long term oxygen therapy (> 15 h a day)

          -  Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further
             criteria)

          -  Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically
             significant bronchiectasis

          -  Patients with a history of asthma (with further criteria)

          -  Patients with Type I or uncontrolled Type II diabetes

          -  Patients with contraindications for tiotropium

          -  Patients who have clinically relevant laboratory abnormalities or a clinically
             significant abnormality

          -  Any patient with active cancer or a history of cancer with less than 5 years disease
             free survival time

          -  Patients with a history of long QT syndrome or whose QTc interval is prolonged

          -  Patients with a hypersensitivity to any of the study drugs or drugs with similar
             chemical structures

          -  Patients who have had treatment with the investigational drug (with further criteria)

          -  Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or
             during run-in period

          -  Patients with known history of non compliance to medication

          -  Patients unable to satisfactorily use a dry powder inhaler device or perform
             spirometry measurements

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00719472 (phase 3, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, chop (cyclophosphamide, hydroxydaunorubicin [doxorubicin], oncovin [vincristine], prednisone), cvp (cyclophosphamide, vincristine, prednisone), analgesic/antipyretic and antihistamine drugs
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥ 18 years

          -  Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) who are
             scheduled to receive rituximab 375 mg/m^2 plus CHOP (cyclophosphamide,
             hydroxydaunorubicin [also called doxorubicin or adriamycin], Oncovin [vincristine],
             prednisone or prednisolone) chemotherapy, or previously untreated follicular
             non-Hodgkin lymphoma (NHL) who are scheduled to receive rituximab 375 mg/m^2 plus CVP
             (cyclophosphamide, vincristine, prednisolone) chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

        Exclusion Criteria:

        * Clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial
        infarction, unstable angina), New York Heart Association (NYHA) Classification Grade II or
        greater congestive heart failure, a ventricular arrhythmia requiring medication within 1
        year prior to Day 1, or NYHA Grade II or greater peripheral vascular disease on Day 1
        (first day of treatment)

        Patients who meet any of the following criteria will be excluded from further study
        participation after Cycle 1:

          -  Circulating lymphocyte count > 5,000/μL before the Cycle 2 rituximab infusion

          -  Development of a serious and/or Grade 3 or 4 adverse event during Cycle 1 judged by
             the investigator to be related to the rituximab infusion

          -  Prior premedication with additional corticosteroids other than the prednisone included
             in the chemotherapy regimens
Clinical trial NCT00335452 (phase 3, status: completed)
Conditions: acute coronary disease, angina unstable
ICD codes: I24.0, I20.0, I25.110, I25.750, I25.700, I25.790, I25.710, I25.720
Drugs: clopidogrel, acetylsalicyclic acid (asa)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with acute coronary disease with clinical symptoms and at least
             electrocardiogram changes or cardiac enzymes elevated

        Exclusion Criteria:

          -  Use of anticoagulants within 10 days with an international normalized ratio (INR) >
             1.5 or planned use during the hospitalisation period

          -  Administration of clopidogrel > 75 mg prior to randomization

          -  Contraindication to clopidogrel or aspirin

          -  Active bleeding or significant risk of bleeding
Clinical trial NCT00700817 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, sitagliptin, metformin, liraglutide
SMILES: CN(C)C(=N)NC(N)=N, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Treatment with metformin alone for at least three months

          -  HbA1c (glycosylated haemoglobin A1c) 7.5-10.0% (both inclusive)

          -  Body Mass Index (BMI) less than or equal to 45.0

        Exclusion Criteria:

          -  Previous treatment with insulin, glucagon like peptide-1 (GLP-1) receptor agonists or
             dipeptidyl peptidase-4 (DPP-4) inhibitors

          -  Treatment with anti-diabetic drugs other than metformin within the last three months

          -  Any serious medical condition

          -  Females who are pregnant, have the intention of becoming pregnant or are breastfeeding
Clinical trial NCT00399035 (phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cediranib, folfox (5-fluorouracil, leucovorin, oxaliplatin), xelox (capecitabine and oxaliplatin), cediranib placebo
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Written Informed Consent

          -  Carcinoma of the colon or rectum

          -  One or more measurable lesions

        Exclusion Criteria:

          -  Adjuvant/neoadjuvant therapy within 6-12 months of study entry

          -  Untreated unstable brain or meningeal metastases

          -  Specific laboratory ranges

          -  Specific cardiovascular problems

          -  Participation in other trials within 30 days
Clinical trial NCT01212991 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: enzalutamide, placebo
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Randomized, Double Blind Treatment Period:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate without neuroendocrine
             differentiation or small cell features

          -  Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy

          -  Progressive disease despite androgen deprivation therapy as defined by rising PSA
             levels or progressive soft tissue or bony disease

          -  No prior treatment with cytotoxic chemotherapy

          -  Asymptomatic or mildly symptomatic from prostate cancer

        Exclusion Criteria:

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment

          -  Known or suspected brain metastasis or active leptomeningeal disease

          -  History of another malignancy within the previous 5 years other than curatively
             treated non-melanomatous skin cancer

        Open-Label Treatment Period:

        The following inclusion criteria apply to patients receiving enzalutamide or placebo during
        double-blind treatment.

        Eligible patients must meet all inclusion criteria.

          -  Received randomized double-blind treatment in PREVAIL;

          -  Open-label day 1 visit is within 6 months after this amendment is approved and becomes
             effective at the study site;

          -  Is willing to maintain androgen deprivation therapy with a gonadotropin-releasing
             hormone (GnRH) agonist/antagonist or has had a bilateral orchiectomy;

        The exclusion criteria apply only to patients starting new treatment with enzalutamide
        after receiving placebo as randomized treatment. Each patient must not meet any of the
        following criteria:

          -  Has taken commercially available enzalutamide (Xtandi);

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment

          -  Known or suspected brain metastasis or active leptomeningeal disease
Clinical trial NCT00668759 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: vernakalant injection, amiodarone injection:
SMILES: COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1, CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have symptomatic AF of 3 to 48 hours duration at baseline.

          -  Be eligible for cardioversion.

          -  Have adequate anticoagulation therapy for cardioversion in accordance with standard of
             practice as recommended by ACC/AHA/ESC guidelines [1].

          -  Be hemodynamically stable and have systolic blood pressure (BP) above 100 mmHg and
             less than 160 mmHg and diastolic BP less than 95 mmHg at screening and baseline.

        Key Exclusion Criteria:

          -  Known or suspected prolonged QT or uncorrected QT interval of >440 msec as measured at
             screening on a 12 lead ECG, familial long QT syndrome, or previous torsades de
             pointes, ventricular fibrillation; or sustained ventricular tachycardia (VT).

          -  Symptomatic bradycardia, sick sinus syndrome, or ventricular rate less than 50 beats
             per minute (bpm) as documented by 12-lead ECG at screening.

          -  A QRS interval >140 msec.

          -  Atrial flutter.

          -  Significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive
             cardiomyopathy or constrictive pericarditis.

          -  Documented previous episodes of second or third degree atrioventricular (AV) block.

          -  Had a myocardial infarction (MI), acute coronary syndrome or cardiac surgery within 30
             days prior to entry into the study.

          -  Uncorrected electrolyte imbalance of serum potassium or magnesium. Both K+ and Mg2+
             must be corrected prior to dosing.
Clinical trial NCT00471146 (phase 3, status: completed)
Conditions: carcinoma, pancreatic ductal
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: ag-013736, gemcitabine, gemcitabine, placebo
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed, metastatic or locally-, advanced pancreatic
             adenocarcinoma not amenable to curative resection.

          -  Adequate renal, hepatic and bone marrow function.

          -  Performance status 0 or 1.

        Exclusion Criteria:

          -  Prior treatment with any systemic chemotherapy for metastatic disease.

          -  Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth
             factor inhibitors.

          -  Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent.

          -  Inability to take oral medication.